Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthem, Inc. stock logo
ANTX
Anthem
$4.69
-3.3%
$3.45
$1.00
$6.91
$174.58M-0.95328,847 shs317,556 shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$24.52
+1.2%
$16.97
$89.95
$99.05
$710.71M0.9553,591 shs538,974 shs
LWAC
LightWave Acquisition
$10.18
$10.15
$9.81
$10.20
$306.16MN/A6,931 shs622 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$8.56
+3.6%
$8.40
$2.80
$8.97
$308.66M0.6337,931 shs1.49 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthem, Inc. stock logo
ANTX
Anthem
0.00%-2.50%+44.18%+327.01%+285.19%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00%-3.00%+56.42%+45.53%+94.15%
LWAC
LightWave Acquisition
0.00%0.00%-0.25%+0.74%-33.10%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%+3.26%+3.13%-14.31%-40.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthem, Inc. stock logo
ANTX
Anthem
$4.69
-3.3%
$3.45
$1.00
$6.91
$174.58M-0.95328,847 shs317,556 shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$24.52
+1.2%
$16.97
$89.95
$99.05
$710.71M0.9553,591 shs538,974 shs
LWAC
LightWave Acquisition
$10.18
$10.15
$9.81
$10.20
$306.16MN/A6,931 shs622 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$8.56
+3.6%
$8.40
$2.80
$8.97
$308.66M0.6337,931 shs1.49 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthem, Inc. stock logo
ANTX
Anthem
0.00%-2.50%+44.18%+327.01%+285.19%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00%-3.00%+56.42%+45.53%+94.15%
LWAC
LightWave Acquisition
0.00%0.00%-0.25%+0.74%-33.10%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%+3.26%+3.13%-14.31%-40.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anthem, Inc. stock logo
ANTX
Anthem
1.00
SellN/AN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
LWAC
LightWave Acquisition
1.00
SellN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ANTX, AVTE, LWAC, and SBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2026
LWAC
LightWave Acquisition
UpgradeSell (E+)Sell (D-)
4/7/2026
Anthem, Inc. stock logo
ANTX
Anthem
Initiated CoverageSell (D-)
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/A$1.94 per shareN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
LWAC
LightWave Acquisition
N/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anthem, Inc. stock logo
ANTX
Anthem
-$35.17M-$1.16N/AN/AN/AN/A-55.04%-49.13%N/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/A
LWAC
LightWave Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A

Latest ANTX, AVTE, LWAC, and SBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/17/2026Q4 2025
Anthem, Inc. stock logo
ANTX
Anthem
N/A-$0.29N/A-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/AN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
LWAC
LightWave Acquisition
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anthem, Inc. stock logo
ANTX
Anthem
N/A
6.87
6.87
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
LWAC
LightWave Acquisition
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Anthem, Inc. stock logo
ANTX
Anthem
90.47%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
LWAC
LightWave Acquisition
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Anthem, Inc. stock logo
ANTX
Anthem
20.79%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
LWAC
LightWave Acquisition
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anthem, Inc. stock logo
ANTX
Anthem
N/A36.00 million28.51 millionNot Optionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
LWAC
LightWave Acquisition
N/A30.08 millionN/ANot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
10 Fun Facts About Mountain Gorillas
ARS Pharmaceuticals Inc (SPRY)
Wild Isles
A look back at RNA Therapeutics – day one
SPRY ARS Pharmaceuticals, Inc.
FDA accepts ARS Pharma’s NDA for Neffy
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

Media Sentiment Over Time

Anthem stock logo

Anthem NASDAQ:ANTX

$4.69 -0.16 (-3.30%)
Closing price 04:00 PM Eastern
Extended Trading
$4.50 -0.19 (-4.05%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$24.52 +0.29 (+1.20%)
As of 05/4/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

LightWave Acquisition NASDAQ:LWAC

$10.18 0.00 (0.00%)
Closing price 03:59 PM Eastern
Extended Trading
$10.18 0.00 (-0.05%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Locust Walk Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Boston, Massachusetts.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$8.56 +0.30 (+3.63%)
As of 05/1/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.